SCHEMBL256798

SCHEMBL256798

COc1ccc(F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
NFE2L2 Q16236 2/20 0.47
ACHE P22303 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
TUBB1 Q9H4B7 2/20 0.43
PTGS1 P23219 2/20 0.43
SLC6A2 P23975 4/20 0.42
SLC6A4 P31645 4/20 0.42
SLC6A3 Q01959 3/20 0.42
PTGS2 P35354 2/20 0.42
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
ALOX15 P16050 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20565314 0.85 NFE2L2 (0.43) MAPTALDH1A1LMNANFE2L2KDM4E
SCHEMBL4439280 0.83 SLC6A4 (0.53) PTGS1SLC6A2SLC6A4SLC6A3PTGS2
SCHEMBL14499414 0.83 PTGS2 (0.49) MAPTALDH1A1LMNANFE2L2KDM4E
SCHEMBL22820110 0.81 PTGS2 (0.51) MAPTALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL12004 0.81 TUBB1 (0.43) MAPTNFE2L2ACHEHTTSMN1; SMN2
SCHEMBL166380 0.80 NFE2L2 (0.61) ALDH1A1NFE2L2ACHEKDM4EPTGS1
SCHEMBL18472613 0.80 NFE2L2 (0.61) ALDH1A1NFE2L2ACHEKDM4EPTGS1
SCHEMBL27493826 0.79 SLC6A4 (0.40) MAPTALDH1A1LMNANFE2L2ACHE
SCHEMBL26331263 0.79 SLC6A4 (0.40) MAPTALDH1A1LMNAACHESLC6A2
SCHEMBL2099198 0.79 SLC6A4 (0.40) MAPTALDH1A1LMNANFE2L2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1812784-A New use i BIOVITRUM AB (SE) 2006-08-02 CN claimed
CN-119189446-A Glass and upright column assembly with film layer and vehicle 福耀玻璃工业集团股份有限公司 2024-12-27 CN disclosed
EP-3608312-B1 SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF XIAMEN VIVOHEALTHS TECH CO LTD (CN) 2024-06-26 EP disclosed
WO-2024015055-A1 PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER THRYV THERAPEUTICS INC. (CA) 2024-01-18 WO disclosed
WO-2024011307-A1 PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER THRYV THERAPEUTICS INC. (CA) 2024-01-18 WO disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
WO-2023150374-A1 INDUCERS OF KLF2 AND METHODS OF USE THEREOF RIPARIAN PHARMACEUTICALS, INC. (US) 2023-08-10 WO disclosed
US-20230203007-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS X-CHEM GLOBAL HQ 2023-06-29 US disclosed
US-20230203007-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS X-CHEM GLOBAL HQ 2023-06-29 US disclosed
US-20230183263-A1 COMBINATION FOR TREATING HEPATITIS B FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) 2023-06-15 US disclosed
WO-2005087228-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-22 WO disclosed
WO-2005028452-A9 SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS PFIZER LTD (GB) 2005-07-21 WO disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
WO-2005002552-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
WO-2004085408-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES MITSUBISHI PHARMA CORPORATION (JP) 2004-10-07 WO disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed
EP-0307777-B1 2-METHYL-4-FLUORO-PHENOLS AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1993-01-07 EP disclosed
US-4885388-A CHEMICAL INTERMEDIATES FOR THE PREPARATION OF HERBICIDES AND PLANT GROWTH REGULATORS BAYER AKTIENGESELLSCHAFT (DE) 1989-12-05 US disclosed
EP-0307777-A2 2-Methyl-4-fluoro-phenols and process for their preparation BAYER AG (DE) 1989-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183263-A1 COMBINATION FOR TREATING HEPATITIS B HAVCR2, SLC10A1, NR1H4 MAPT 3432/4885ALDH1A1 567/4885LMNA 2421/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A MAPT 4256/4885ALDH1A1 433/4885LMNA 2851/4885
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 MAPT 3721/4885ALDH1A1 915/4885LMNA 3416/4885
US-20230203007-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1A, SCN3A, SCN2A MAPT 236/4885ALDH1A1 1110/4885LMNA 442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.